GlobalData on MSN18h
AstraZeneca secures first BTK approval in first-line mantle cell lymphoma
The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.
FDA Approves Two Breakthrough Cancer Treatments for AstraZeneca
New Treatments for HR-Positive Breast Cancer and Mantle Cell Lymphoma Offer Promising Outcomes and Expanded Options for ...
Zacks.com on MSN12h
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...
Brooklyn Investment Group Grows Position in AstraZeneca PLC (NASDAQ:AZN)
Brooklyn Investment Group grew its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 3,313.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,775 shares of the ...
Gateway Investment Advisers LLC Sells 1,754 Shares of AstraZeneca PLC (NASDAQ:AZN)
Gateway Investment Advisers LLC cut its stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 35.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and ...
AstraZeneca’s Strong Growth Forecasts and Strategic Position Justify Buy Rating Despite Market Concerns
Sachin Jain, an analyst from Bank of America Securities, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price ...
Bank of America Securities Remains a Buy on AstraZeneca (AZN)
In a report released today, Sachin Jain from Bank of America Securities reiterated a Buy rating on AstraZeneca (AZN – Research Report), with a ...